ABCG2, CD44 and SOX9 are increased with the acquisition of drug resistance and involved in cancer stem cell activities in head and neck squamous cell carcinoma cells

Murakami,Koichi; Umemura,Naoki; Adachi,Makoto; Motoki,Masahiro; Ohkoshi,Emika

doi:10.3892/etm.2022.11658

ABCG2, CD44 and SOX9 are increased with the acquisition of drug resistance and involved in cancer stem cell activities in head and neck squamous cell carcinoma cells

Authors:
- Koichi Murakami
- Naoki Umemura
- Makoto Adachi
- Masahiro Motoki
- Emika Ohkoshi
View Affiliations

Affiliations: Department of Natural Products Chemistry, Faculty of Pharmaceutical Sciences Aomori University, Aomori, Aomori 030‑0943, Japan, Department of Oral Biochemistry, Asahi University School of Dentistry, Mizuho, Gifu 501‑0296, Japan, Department of Oral and Maxillofacial Surgery, Nagoya Tokushukai General Hospital, Kasugai, Aichi 487‑0016, Japan
Published online on: October 18, 2022 https://doi.org/10.3892/etm.2022.11658
Article Number: 722
Copyright: © Murakami et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancer stem cells are a sub‑population of cancer cells with self‑renewal activity that play key roles in tumor resistance to chemotherapy and radiation. Several cancer stem cell markers have been identified to correlate with clinical prognosis. However, which marker is associated with which cancer stem cell characteristic is unclear. The present study aimed to clarify the relationship between cancer stem cell markers associated with drug resistance acquisition and the characteristics of cancer stem cells. We generated cisplatin‑resistant head and neck squamous cell carcinoma cells by culturing cells in increasing concentrations of cisplatin. The cisplatin‑resistant head and neck squamous cell carcinoma cells also acquired multidrug resistance and were named resistant HSC‑3 (R HSC‑3) cells. R HSC‑3 showed no differences in cell proliferation or cell cycle distributions compared with parental cells. R HSC‑3 cells showed increased drug excretion ability and elevated expression of ATP‑binding cassette subfamily G member 2 (ABCG2), a drug excretion pump. R HSC‑3 cells also highly expressed CD44, a cancer stem cell marker, and exhibited enhanced cell invasion and spheroid formation abilities. Furthermore, the stem cell‑related factor SRY‑box transcription factor 9 (SOX9) was identified as increased in R HSC‑3 cells by microarray analysis. Knockdown experiments showed that SOX9 and ABCG2 were involved in the drug excretion ability of R HSC3 cells and ABCG2 was involved in the spheroid formation ability of R HSC‑3 cells. These results indicate that CD44, SOX9 and ABCG2 expression levels were enhanced in head and neck squamous cell carcinoma cells that acquired multidrug resistance and that these molecules are important for maintaining cancer stem cell characteristics. Overall, regulating CD44, SOX9 and ABCG2 may be a strategy to inhibit cancer stem cells.

View Figures

View References

1	Scadden DT: Cancer stem cells refined. Nat Immunol. 5:701–703. 2004.PubMed/NCBI View Article : Google Scholar
2	Visvader JE and Lindeman GJ: Cancer stem cells: Current status and evolving complexities. Cell Stem Cell. 10:717–728. 2012.PubMed/NCBI View Article : Google Scholar
3	Magee JA, Piskounova E and Morrison SJ: Cancer stem cells: Impact, heterogeneity, and uncertainty. Cancer Cell. 21:283–296. 2012.PubMed/NCBI View Article : Google Scholar
4	Chen D, Wu M, Li Y, Chang L, Yuan Q, Ekimyan-Salvo M, Deng P, Yu B, Yu Y, Dong J, et al: Targeting BMI1+ cancer stem cells overcomes chemoresistance and inhibits metastases in squamous cell carcinoma. Cell Stem Cell. 20:621–634. 2017.PubMed/NCBI View Article : Google Scholar
5	White RA, Neiman JM, Reddi A, Han G, Birlea S, Mitra D, Dionne L, Fernandez P, Murao K, Bian L, et al: Epithelial stem cell mutations that promote squamous cell carcinoma metastasis. J Clin Invest. 123:4390–4404. 2013.PubMed/NCBI View Article : Google Scholar
6	Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 444:756–760. 2006.PubMed/NCBI View Article : Google Scholar
7	Meacham CE and Morrison SJ: Tumour heterogeneity and cancer cell plasticity. Nature. 501:328–337. 2013.PubMed/NCBI View Article : Google Scholar
8	Li J, Condello S, Thomes-Pepin J, Ma X, Xia Y, Hurley TD, Matei D and Cheng JX: Lipid desaturation is a metabolic marker and therapeutic target of ovarian cancer stem cells. Cell Stem Cell. 20:303–314, e305. 2017.PubMed/NCBI View Article : Google Scholar
9	Codd AS, Kanaseki T, Torigo T and Tabi Z: Cancer stem cells as targets for immunotherapy. Immunology. 153:304–314. 2018.PubMed/NCBI View Article : Google Scholar
10	Ohkoshi E and Umemura N: Induced overexpression of CD44 associated with resistance to apoptosis on DNA damage response in human head and neck squamous cell carcinoma cells. Int J Oncol. 50:387–395. 2017.PubMed/NCBI View Article : Google Scholar
11	Nanbu T, Umemura N, Ohkoshi E, Nanbu K, Sakagami H and Shimada J: Combined SN-38 and gefitinib treatment promotes CD44 degradation in head and neck squamous cell carcinoma cells. Oncol Rep. 39:367–375. 2018.PubMed/NCBI View Article : Google Scholar
12	Pena-Solorzano D, Stark SA, Konig B, Sierra CA and Ochoa-Puentes C: ABCG2/BCRP: Specific and nonspecific modulators. Med Res Rev. 37:987–1050. 2016.PubMed/NCBI View Article : Google Scholar
13	Chen Z, Shi T, Zhang L, Zhu P, Deng M, Huang C, Hu T, Jiang L and Li J: Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 370:153–164. 2016.PubMed/NCBI View Article : Google Scholar
14	Lu BC, Li J, Yu WF, Zhang GZ, Wang HM and Ma HM: Elevated expression of Nrf2 mediates multidrug resistance in CD133+ head and neck squamous cell carcinoma stem cells. Oncol Lett. 12:4333–4338. 2016.PubMed/NCBI View Article : Google Scholar
15	Guan GF, Zhang DJ, Zheng Y, Wen LJ, Yu DJ, Lu YQ and Zhao Y: Significance of ATP-binding cassette transporter proteins in multidrug resistance of head and neck squamous cell carcinoma. Oncol Lett. 10:631–636. 2015.PubMed/NCBI View Article : Google Scholar
16	Hu J, Li J, Yue X, Wang J, Liu J, Sun L and Kong D: Expression of the cancer stem cell markers ABCG2 and OCT-4 in right-sided colon cancer predicts recurrence and poor outcomes. Oncotarget. 8:28463–28470. 2017.PubMed/NCBI View Article : Google Scholar
17	Xiong B, Ma L, Hu X, Zhang C and Cheng Y: Characterization of side population cells isolated from the colon cancer cell line SW480. Int J Oncol. 45:1175–1183. 2014.PubMed/NCBI View Article : Google Scholar
18	Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, et al: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 357:1705–1715. 2007.PubMed/NCBI View Article : Google Scholar
19	Bolstad BM, Irizarry RA, Astrand M and Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 19:185–193. 2003.PubMed/NCBI View Article : Google Scholar
20	Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, et al: Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol. 5(R80)2004.PubMed/NCBI View Article : Google Scholar
21	Quackenbush J: Microarray data normalization and transformation. Nat Genet. 32 Suppl:S496–S501. 2002.PubMed/NCBI View Article : Google Scholar
22	Takeishi S and Nakayama KI: Role of Fbxw7 in the maintenance of normal stem cells and cancer-initiating cells. Br J Cancer. 111:1054–1059. 2014.PubMed/NCBI View Article : Google Scholar
23	Takeishi S, Matsumoto A, Onoyama I, Naka K, Hirao A and Nakayama KI: Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence. Cancer Cell. 23:347–361. 2013.PubMed/NCBI View Article : Google Scholar
24	Saito Y, Uchida N, Tanaka S, Suzuki N, Tomizawa-Murasawa M, Sone A, Najima Y, Takagi S, Aoki Y, Wake A, et al: Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat Biotechnol. 28:275–280. 2010.PubMed/NCBI View Article : Google Scholar
25	Kukal S, Guin D, Rawat C, Bora S, Mishra MK, Sharma P, Paul PR, Kanojia N, Grewal GK, Kukreti S, et al: Multidrug efflux transporter ABCG2: Expression and regulation. Cell Mol Life Sci. 78:6887–6939. 2021.PubMed/NCBI View Article : Google Scholar
26	Fletcher JI, Haber M, Henderson MJ and Norris MD: ABC transporters in cancer: More than just drug efflux pumps. Nat Rev Cancer. 10:147–156. 2010.PubMed/NCBI View Article : Google Scholar
27	Moniot B, Declosmenil F, Barrionuevo F, Scherer G, Aritake K, Malki S, Marzi L, Cohen-Solal A, Georg I, Klattig J, et al: The PGD2 pathway, independently of FGF9, amplifies SOX9 activity in Sertoli cells during male sexual differentiation. Development. 136:1813–1821. 2009.PubMed/NCBI View Article : Google Scholar
28	Chaffer CL, Dopheide B, Savagner P, Thompson EW and Williams ED: Aberrant fibroblast growth factor receptor signaling in bladder and other cancers. Differentiation. 75:831–842. 2007.PubMed/NCBI View Article : Google Scholar
29	Giancotti FG: Mechanisms governing metastatic dormancy and reactivation. Cell. 155:750–764. 2013.PubMed/NCBI View Article : Google Scholar
30	Modok S, Mellor HR and Callaghan R: Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol. 6:350–354. 2006.PubMed/NCBI View Article : Google Scholar
31	Kage K, Tsukahara S, Sugiyama T, Asada S, Ishikawa E, Tsuruo T and Sugimoto Y: Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization. Int J Cancer. 97:626–630. 2002.PubMed/NCBI View Article : Google Scholar
32	Suresh R, Ali S, Ahmad A, Philip PA and Sarkar FH: The role of cancer stem cells in recurrent and drug-resistant lung cancer. Adv Exp Med Biol. 890:57–74. 2016.PubMed/NCBI View Article : Google Scholar
33	Nieh S, Jao SW, Yang CY, Lin YS, Tseng YH, Liu CL, Lee TY, Liu TY, Chu YH and Chen SF: Regulation of tumor progression via the Snail-RKIP signaling pathway by nicotine exposure in head and neck squamous cell carcinoma. Head Neck. 37:1712–1721. 2015.PubMed/NCBI View Article : Google Scholar
34	Wang J, Wu Y, Gao W, Li F, Bo Y, Zhu M, Fu R, Liu Q, Wen S and Wang B: Identification and characterization of CD133+CD44+ cancer stem cells from human laryngeal squamous cell carcinoma cell lines. J Cancer. 8:497–506. 2017.PubMed/NCBI View Article : Google Scholar
35	Lee Y, Shin JH, Longmire M, Wang H, Kohrt HE, Chang HY and Sunwoo JB: CD44+ cells in head and neck squamous cell carcinoma suppress T-cell-mediated immunity by selective constitutive and inducible expression of PD-L1. Clin Cancer Res. 22:3571–3581. 2016.PubMed/NCBI View Article : Google Scholar
36	Wagner T, Wirth J, Meyer J, Zabel B, Held M, Zimmer J, Pasantes J, Bricarelli FD, Keutel J, Hustert E, et al: Autosomal sex reversal and campomelic dysplasia are caused by mutations in and around the SRY-related gene SOX9. Cell. 79:1111–1120. 1994.PubMed/NCBI View Article : Google Scholar
37	Tanaka J, Mabuchi Y, Hata K, Yasuhara R, Takamatsu K, Kujiraoka S, Yukimori A, Takakura I, Sumimoto H, Fukada T, et al: Sox9 regulates the luminal stem/progenitor cell properties of salivary glands. Exp Cell Res. 382(111449)2019.PubMed/NCBI View Article : Google Scholar
38	Khorani K, Schwaerzler J, Burkart S, Kurth I, Holzinger D, Flechtenmacher C, Plinkert PK, Zaoui K and Hess J: Establishment of a plasticity-associated risk model based on a SOX2- and SOX9-related gene set in head and neck squamous cell carcinoma. Mol Cancer Res. 19:1676–1687. 2021.PubMed/NCBI View Article : Google Scholar
39	Al-Zahrani KN, Abou-Hamad J, Pascoal J, Labreche C, Garland B and Sabourin LA: AKT-mediated phosphorylation of Sox9 induces Sox10 transcription in a murine model of HER2-positive breast cancer. Breast Cancer Res. 23(55)2021.PubMed/NCBI View Article : Google Scholar